TP53 and hepatocellular carcinoma: Consistent with our results for all m6A regulators, amplification/copy number gain of VIRMA was significantly correlated with poorer clinical stage and the presence of TP53 and TERT mutation in this HCC cohort (P =0.04, P = 0.027, respectively; Table S4).